Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107

Leukemia volume 19, pages 1670–1671 (2005)Cite this article

TO THE EDITOR

We conclude that AMN107 constitutes a promising candidate for the treatment of systemic mastocytosis, a disease which is typically driven by the imatinib-resistant, activating cKit mutation D816V.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–580.

    Article  CAS  PubMed  Google Scholar 

  2. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726–727.

    CAS  PubMed  Google Scholar 

  3. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312–314.

    Article  CAS  PubMed  Google Scholar 

  4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.

    Article  CAS  PubMed  Google Scholar 

  5. Kindler T, Breitenbuecher F, Marx A, Beck J, Hess G, Weinkauf B et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103: 3644–3654.

    Article  CAS  PubMed  Google Scholar 

  6. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741–1744.

    Article  CAS  PubMed  Google Scholar 

  7. Kantarjian HM, Ottmann O, Cortes J, Wassmann B, Jones D, Hochhaus A et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML). ASCO, Orlando 2005. p 195s.

  8. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–141.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. N von Bubnoff and S H P Gorantla: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Internal Medicine III, Technical University of Munich, Munich, Germany

    N von Bubnoff, S H P Gorantla, R K Kancha, F Lordick, C Peschel & J Duyster

Authors
  1. N von Bubnoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S H P Gorantla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R K Kancha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Lordick
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Peschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Duyster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Duyster.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Bubnoff, N., Gorantla, S., Kancha, R. et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19, 1670–1671 (2005). https://doi.org/10.1038/sj.leu.2403887

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403887

This article is cited by

Search

Advanced search

Quick links